Skip to content

Study on the mechanism of metformin inhibiting the proliferation of uterine leiomyoma cells by affecting AMPK mTOR

Study on the mechanism of metformin inhibiting the proliferation of uterine leiomyoma cells by affecting AMPK mTOR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099747
Enrollment
Unknown
Registered
2025-03-27
Start date
2025-03-30
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leiomyoma

Interventions

Normal uterine smooth muscle cells control group:None
Metformin group (different concentration gradients):0, 1, 5, 10 mmol/L, concentrations optimized according to pre-experiments

Sponsors

The First Affiliated Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosis of uterine leiomyoma: Patients diagnosed with uterine leiomyoma through imaging examinations such as ultrasound and MRI. The diagnostic criteria include the size, location, and morphological characteristics of the fibroids, as well as the exclusion of other similar lesions (such as endometriosis) Symptoms, adenomyosis, etc (2) Physical health; (3) Clinical symptoms: There are obvious clinical symptoms, such as abnormal uterine bleeding, lower abdominal pain, compression symptoms, etc Some patients may experience anemia or other complications due to fibroids, requiring medication to alleviate symptoms; Patients who require surgical treatment; (4) Not pregnant or breastfeeding; (5) Exclude other diseases: Exclude other diseases that may cause similar symptoms, such as endometriosis, adenomyosis, etc Serious liver and kidney dysfunction, blood system diseases, infectious diseases, etc. were excluded; (6) Willing and able to participate with informed consent;

Exclusion criteria

Exclusion criteria: (1) Serious complications: Patients with severe anemia and anemia related complications (such as heart failure) Patients with severe liver and kidney dysfunction (2) Drug contraindications: For patients who are allergic to research drugs or allergic to drug ingredients Never used hypoglycemic drugs Previously used medication to treat uterine fibroids (3) Pregnant or lactating women: (4) Other situations: Patients with severe mental illness or inability to cooperate with the study Patients with suicidal tendencies or a history of mental illness

Design outcomes

Primary

MeasureTime frame
Proliferation index;AMPK expression level;

Countries

China

Contacts

Public ContactGuan Yutao

The First Affiliated Hospital of Ningbo University

2309732100@qq.com+86 135 6603 6278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026